<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03303066</url>
  </required_header>
  <id_info>
    <org_study_id>FGCL-4592-813</org_study_id>
    <nct_id>NCT03303066</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of FG-4592 for Treatment of Anemia in Subjects With Lower Risk MDS</brief_title>
  <official_title>A Phase 2/3 Trial of FG-4592 for Treatment of Anemia in Subjects With Lower Risk Myelodysplastic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>FibroGen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study to evaluate the efficacy and safety of FG-4592 for the treatment
      of anemia in Chinese subjects with lower risk MDS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2/3 trial with sequential Phase 2 and Phase 3 components. In each, there is
      an up to 4 weeks screen period followed by a treatment period of 26 weeks and a 4 week follow
      up period.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of subjects with a hemoglobin response to FG-4592 without transfusion</measure>
    <time_frame>26 weeks</time_frame>
    <description>Efficacy of roxadustat (FG-4592) in achieving hemoglobin correction and maintenance and reducing the number of red blood cell packs transfused in 26 weeks in comparison to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the incidence of treatment emergent adverse events and tolerability of roxadustat</measure>
    <time_frame>30 weeks</time_frame>
    <description>Adverse events, serious adverse events, vital signs, electrocardiograms, blood pressure, heart rate, and physical exams</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) of subjects with hemoglobin increase ≥ 1.5 g/dL from baseline</measure>
    <time_frame>26 weeks</time_frame>
    <description>Efficacy of roxadustat (FG-4592) in achieving hemoglobin correction in 26 weeks in comparison to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first hemoglobin response</measure>
    <time_frame>26 weeks</time_frame>
    <description>Impact of roxadustat (FG-4592) in achieving hemoglobin correction in 26 weeks in comparison to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in hemoglobin in Week 25 to 27</measure>
    <time_frame>2 weeks</time_frame>
    <description>Impact of roxadustat (FG-4592) on hemoglobin correction and maintenance in Week 25 to 27 in comparison to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with mean Hb ≥ 10.0 g/dL</measure>
    <time_frame>30 weeks</time_frame>
    <description>Efficacy of roxadustat (FG-4592) in achieving hemoglobin correction and maintenance in comparison to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of transfusions over the treatment period</measure>
    <time_frame>26 weeks</time_frame>
    <description>Impact of roxadustat (FG-4592) in the number of red blood cell packs transfused in 26 weeks in comparison to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of roxadustat on quality of life measured by FACT-An and FACIT-F</measure>
    <time_frame>30 weeks</time_frame>
    <description>Change in raw score from baseline as measured by FACT-An and FACIT-F</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change from baseline to maximum hemoglobin level</measure>
    <time_frame>30 weeks</time_frame>
    <description>Impact of roxadustat (FG-4592) in achieving hemoglobin correction and maintenance in comparison to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Time to maximum hemoglobin increase</measure>
    <time_frame>26 weeks</time_frame>
    <description>Efficacy of roxadustat (FG-4592) in achieving hemoglobin correction in 26 weeks in comparison to baseline</description>
  </other_outcome>
  <other_outcome>
    <measure>Duration of transfusion independence</measure>
    <time_frame>30 weeks</time_frame>
    <description>Evaluate transfusion independence by measuring the number of red blood cell packs transfused throughout the course of the study in comparison to baseline</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">175</enrollment>
  <condition>Primary MDS Classified as Very Low, Low or Intermediate Risk With &lt;5% Blasts</condition>
  <arm_group>
    <arm_group_label>FG-4592 (Open Label, Double-blind, Three times a week)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fixed starting doses (different doses for lower body weight &amp; higher body weight); dose adjustments to hemoglobin levels are allowed during the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Double-blind, Three times a week)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Fixed starting doses (different doses for lower body weight &amp; higher body weight); dose adjustments to hemoglobin levels are allowed during the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FG-4592</intervention_name>
    <description>Oral</description>
    <arm_group_label>FG-4592 (Open Label, Double-blind, Three times a week)</arm_group_label>
    <other_name>Roxadustat</other_name>
    <other_name>AZD9941</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral</description>
    <arm_group_label>Placebo (Double-blind, Three times a week)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Diagnosis of primary MDS classified as very low, low or intermediate risk with &lt;5%
             blasts of &gt;= 4 weeks duration

          -  Screening Hb &lt;10 g/dL and ≥6g/dL

          -  Transfusion independent defined as no red blood cell transfusions within 12 weeks of
             Day 1

          -  ESA-naïve (less than 4 weeks of ESA treatment in total, and not within 30 days of Day
             1)

          -  ECOG of 0-2 at screen

        Key Exclusion Criteria:

          -  Diagnosis of secondary MDS

          -  Significant myelofibrosis (&gt;2+fibrosis)

          -  Any prior therapy with cyclosporine, antithymocyte globulin, azacitidine, decitabine,
             thalidomide, or lenalidomide

          -  Screen serum erythropoietin level of &gt;200 mIU/mL

          -  Clinically significant anemia due to non-MDS etiologies
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Yang Shen, MD</last_name>
    <phone>86 21 68810687</phone>
    <phone_ext>839</phone_ext>
    <email>yshen@fibrogen.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Xiaoning Cai</last_name>
    <phone>86 18515307508</phone>
    <email>xcai@fibrogen.cn</email>
  </overall_contact_backup>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 2, 2017</study_first_submitted>
  <study_first_submitted_qc>October 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">October 5, 2017</study_first_posted>
  <last_update_submitted>October 2, 2017</last_update_submitted>
  <last_update_submitted_qc>October 2, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Myelodysplastic Syndromes</keyword>
  <keyword>Anemia</keyword>
  <keyword>Hemoglobin (Hb)</keyword>
  <keyword>Low Risk Myelodysplastic Syndrome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

